MedTrace Logo

A Phase II Study of Capecitabine and Docetaxel in Previously Untreated Advanced Non-Small Cell Lung Cancer Patients

NCT00201825 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2014-10-06

Study results available
· View outcomes & findings →

Summary

This study will determine the objective response rate in chemotherapy naive non-small cell lung cancer patients with advanced disease.

Conditions

Interventions

DRUG

Capecitabine

1250 mg/m2/day in 2 oral daily divided doses of 625 mg/m2 on day 5 of every cycle and continued for 14 days.

DRUG

Docetaxel

36 mg/m2 IV weekly for 3 weeks every 4 weeks.

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • Tony Bekaii-Saab

    lead OTHER

Principal Investigators

  • Tony Bekaii-Saab · Ohio State University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-12-31
Primary Completion
2012-12-31
Completion
2013-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00201825 on ClinicalTrials.gov